Effect of 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) on hormones of energy balance in a TCDD-sensitive and a TCDD-resistant rat strain

International Journal of Molecular Sciences

Volumn 15, Issue 8, 2014, Pages 13938-13966

  Lindén, Jere ^a   Lensu, Sanna ^b   Pohjanvirta, Raimo ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF JYVÄSKYLÄ   (Finland)

Author keywords

2,3,7,8 tetrachlorodibenzo p dioxin; Acute toxicity; AHR; Energy balance; Hormones; Strain differences; TCDD; Wasting syndrome

Indexed keywords

2, 3, 7, 8 TETRACHLORODIBENZO PARA DIOXIN; ADIPONECTIN; AROMATIC HYDROCARBON RECEPTOR; CHOLESTEROL; CORN OIL; CORTICOSTERONE; FIBROBLAST GROWTH FACTOR 21; GHRELIN; GLUCAGON; HORMONE; INSULIN; LEPTIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; FIBROBLAST GROWTH FACTOR; MESSENGER RNA;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CLINICAL CHEMISTRY; CONTROLLED STUDY; DIET RESTRICTION; ENERGY BALANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; LIPOLYSIS; MALE; MASS FRAGMENTOGRAPHY; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; WASTING SYNDROME; WEIGHT REDUCTION; WESTERN BLOTTING; ANIMAL; BLOOD; DRUG EFFECTS; ENERGY METABOLISM; GENETICS; LIVER; LONG EVANS RAT; METABOLISM; SPECIES DIFFERENCE; WISTAR RAT;

ADIPONECTIN; ANIMALS; BODY WEIGHT; ENERGY METABOLISM; FIBROBLAST GROWTH FACTORS; GLUCAGON; INSULIN; INSULIN-LIKE GROWTH FACTOR I; LEPTIN; LIVER; RATS; RATS, LONG-EVANS; RATS, WISTAR; RECEPTORS, ARYL HYDROCARBON; RNA, MESSENGER; SPECIES SPECIFICITY; TETRACHLORODIBENZODIOXIN;

EID: 84919887164     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms150813938     Document Type: Article

References (129)

1. Pohjanvirta, R.; Tuomisto, J. Short-term toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in laboratory animals: Effects, mechanisms, and animal models. Pharmacol. Rev. 1994, 46, 483-549.
2. Birnbaum, L.S.; Tuomisto, J. Non-carcinogenic effects of TCDD in animals. Food Addit. Contam. 2000, 17, 275-288.
3. Abbott, B.D. Teratogenic impact of dioxin activated AHR in laboratory animals. In The AH Receptor in Biology and Toxicology; Pohjanvirta, R., Ed.; John Wiley and Sons: Hoboken, NJ, USA, 2012; pp. 257-266.
4. Mocarelli, P.; Gerthoux, P.M.; Needham, L.L.; Patterson, D.G.; Limonta, G.; Falbo, R.; Signorini, S.; Bertona, M.; Crespi, C.; Sarto, C.; et al. Perinatal exposure to low doses of dioxin can permanently impair human semen quality. Environ. Health Perspect. 2011, 119, 713-718.
5. Alaluusua, S.; Lukinmaa, P.L. Developmental dental toxicity of dioxin and related compounds-A review. Int. Dent. J. 2006, 56, 323-331.
6. Pohjanvirta, R.; Korkalainen, M.; Moffat, I.D.; Boutros, P.C.; Okey, A.B. Role of the AHR and its structure in TCDD toxicity. In The AH Receptor in Biology and Toxicology; Pohjanvirta, R., Ed.; John Wiley & Sons: Hoboken, NJ, USA, 2011.
7. Pohjanvirta, R. Transgenic mouse lines expressing rat AH receptor variants-A new animal model for research on AH receptor function and dioxin toxicity mechanisms. Toxicol. Appl. Pharmacol. 2009, 236, 166-182.
8. Lindén, J.; Lensu, S.; Tuomisto, J.; Pohjanvirta, R. Dioxins, the aryl hydrocarbon receptor and the central regulation of energy balance. Front. Neuroendocrinol. 2010, 31, 452-478
9. Pohjanvirta, R.; Miettinen, H.M.; Sankari, S.; Hegde, N.; Lindén, J. Unexpected gender difference in sensitivity to the acute toxicity of dioxin in mice. Toxicol. Appl. Pharmacol. 2012, 262, 167-176.
10. Gasiewicz, T.A.; Neal, R.A. 2,3,7,8-Tetrachlorodibenzo-p-dioxin tissue distribution, excretion, and effects on clinical chemical parameters in guinea pigs. Toxicol. Appl. Pharmacol. 1979, 51, 329-339.
11. Henry, E.C.; Gasiewicz, T.A. Changes in thyroid hormones and thyroxine glucuronidation in hamsters compared with rats following treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol. Appl. Pharmacol. 1987, 89, 165-174.
12. Kelling, C.K.; Christian, B.J.; Inhorn, S.L.; Peterson, R.E. Hypophagia-induced weight loss in mice, rats, and guinea pigs treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Fundam. Appl. Toxicol. 1985, 5, 700-712.
13. Olson, J.R.; Holscher, M.A.; Neal, R.A. Toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in the golden Syrian hamster. Toxicol. Appl. Pharmacol. 1980, 55, 67-78.
14. Geusau, A.; Schmaldienst, S.; Derfler, K.; Päpke, O.; Abraham, K. Severe 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) intoxication: Kinetics and trials to enhance elimination in two patients. Arch. Toxicol. 2002, 76, 316-325.
15. Needham, L.L.; Gerthoux, P.M.; Patterson, D.G.; Brambilla, P.; Turner, W.E.; Beretta, C.; Pirkle, J.L.; Colombo, L.; Sampson, E.J.; Tramacere, P.; et al. Serum dioxin levels in Seveso, Italy, population in 1976. Teratog. Carcinog. Mutagen. 1997, 17, 225-240.
16. Sorg, O.; Zennegg, M.; Schmid, P.; Fedosyuk, R.; Valikhnovskyi, R.; Gaide, O.; Kniazevych, V.; Saurat, J.H. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) poisoning in Victor Yushchenko: Identification and measurement of TCDD metabolites. Lancet 2009, 374, 1179-1185.
17. Schneeberger, M.; Gomis, R.; Claret, M. Hypothalamic and brainstem neuronal circuits controlling homeostatic energy balance. J. Endocrinol. 2014, 220, T25-T46.
18. Banks, W.A.; Owen, J.B.; Erickson, M.A. Insulin in the brain: There and back again. Pharmacol. Ther. 2012, 136, 82-93.
19. Woods, S.C.; Lutz, T.A.; Geary, N.; Langhans, W. Pancreatic signals controlling food intake; insulin, glucagon and amylin. Philos. Trans. R. Soc. B: Biol. Sci. 2006, 361, 1219-1235.
20. Guo, S. Insulin signaling, resistance, and metabolic syndrome: Insights from mouse models into disease mechanisms. J. Endocrinol. 2014, 220, T1-T23.
21. Gerozissis, K. Brain insulin, energy and glucose homeostasis; genes, environment and metabolic pathologies. Eur. J. Pharmacol. 2008, 585, 38-49.
22. Sánchez-Lasheras, C.; Könner, A.C.; Brüning, J.C. Integrative neurobiology of energy homeostasis-neurocircuits, signals and mediators. Front. Neuroendocrinol. 2010, 31, 4-15.
23. Grill, H.J.; Schwartz, M.W.; Kaplan, J.M.; Foxhall, J.S.; Breininger, J.; Baskin, D.G. Evidence that the caudal brainstem is a target for the inhibitory effect of leptin on food intake. Endocrinology 2002, 143, 239-246.
24. Halaas, J.L.; Boozer, C.N.; Blair-West, J.; Fidahusein, N.; Denton, D.A.; Friedman, J.M. Physiological response to long-term peripheral and central leptin infusion in lean and obese mice. Proc. Natl. Acad. Sci. USA 1997, 94, 8878-8883.
25. Könner, A.C.; Klöckener, T.; Brüning, J.C. Control of energy homeostasis by insulin and leptin: Targeting the arcuate nucleus and beyond. Physiol. Behav. 2009, 97, 632-638
26. Sahu, A. Effects of chronic central leptin infusion on proopiomelanocortin and neurotensin gene expression in the rat hypothalamus. Neurosci. Lett. 2008, 440, 125-129.
27. Filippi, B.M.; Abraham, M.A.; Yue, J.T.Y.; Lam, T.K.T. Insulin and glucagon signaling in the central nervous system. Rev. Endocr. Metab. Disord. 2013, 14, 365-375.
28. Berthoud, H.R. Vagal and hormonal gut-brain communication: From satiation to satisfaction. Neurogastroenterol. Motil. 2008, 20, 64-72.
29. Dietrich, M.O.; Horvath, T.L. Feeding signals and brain circuitry. Eur. J. Neurosci. 2009, 30, 1688-1696.
30. Pusztai, P.; Sarman, B.; Ruzicska, E.; Toke, J.; Racz, K.; Somogyi, A.; Tulassay, Z. Ghrelin: A new peptide regulating the neurohormonal system, energy homeostasis and glucose metabolism. Diabetes Metab. Res. Rev. 2008, 24, 343-352.
31. Schellekens, H.; Finger, B.C.; Dinan, T.G.; Cryan, J.F. Ghrelin signalling and obesity: At the interface of stress, mood and food reward. Pharmacol. Ther. 2012, 135, 316-326.
32. Date, Y.; Kojima, M.; Hosoda, H.; Sawaguchi, A.; Mondal, M.S.; Suganuma, T.; Matsukura, S.; Kangawa, K.; Nakazato, M. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 2000, 141, 4255-4261.
33. Kojima, M.; Hosoda, H.; Date, Y.; Nakazato, M.; Matsuo, H.; Kangawa, K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999, 402, 656-660.
34. Kageyama, H.; Takenoya, F.; Shiba, K.; Shioda, S. Neuronal circuits involving ghrelin in the hypothalamus-mediated regulation of feeding. Neuropeptides 2010, 44, 133-138.
35. Begg, D.P.; Woods, S.C. The endocrinology of food intake. Nat. Rev. Endocrinol. 2013, 9, 584-597.
36. Alsahli, M.; Gerich, J.E. Hypoglycemia. Endocrinol. Metab. Clin. N. Am. 2013, 42, 657-676.
37. Ramnanan, C.J.; Edgerton, D.S.; Kraft, G.; Cherrington, A.D. Physiologic action of glucagon on liver glucose metabolism. Diabetes Obes. Metab. 2011, 13, 118-125.
38. Cryer, P.E. Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology 2012, 153, 1039-1048.
39. Parker, J.A.; McCullough, K.A.; Field, B.C.T.; Minnion, J.S.; Martin, N.M.; Ghatei, M.A.; Bloom, S.R. Glucagon and GLP-1 inhibit food intake and increase c-fos expression in similar appetite regulating centres in the brainstem and amygdala. Int. J. Obes. 2013, 37, 1391-1398.
40. Tishinsky, J.M.; Robinson, L.E.; Dyck, D.J. Insulin-sensitizing properties of adiponectin. Biochimie 2012, 94, 2131-2136.
41. Kubota, N.; Yano, W.; Kubota, T.; Yamauchi, T.; Itoh, S.; Kumagai, H.; Kozono, H.; Takamoto, I.; Okamoto, S.; Shiuchi, T.; et al. Adiponectin Stimulates AMP-Activated Protein Kinase in the Hypothalamus and Increases Food Intake. Cell Metab. 2007, 6, 55-68.
42. Bassi, M.; Do Carmo, J.M.; Hall, J.E.; Da Silva, A.A. Chronic effects of centrally administered adiponectin on appetite, metabolism and blood pressure regulation in normotensive and hypertensive rats. Peptides 2012, 37, 1-5.
43. Rose, A.J.; Herzig, S. Metabolic control through glucocorticoid hormones: An update. Mol. Cell. Endocrinol. 2013, 380, 65-78.
44. Rose, A.J.; Vegiopoulos, A.; Herzig, S. Role of glucocorticoids and the glucocorticoid receptor in metabolism: Insights from genetic manipulations. J. Steroid Biochem. Mol. Biol. 2010, 122, 10-20.
45. Stanley, B.G.; Lanthier, D.; Chin, A.S.; Leibowitz, S.F. Suppression of neuropeptide Y-elicited eating by adrenalectomy or hypophysectomy: Reversal with corticosterone. Brain Res. 1989, 501, 32-36.
46. Nishimura, T.; Nakatake, Y.; Konishi, M.; Itoh, N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim. Biophys. Acta-Gene Struct. Expr. 2000, 1492, 203-206.
47. Izumiya, Y.; Bina, H.A.; Ouchi, N.; Akasaki, Y.; Kharitonenkov, A.; Walsh, K. FGF21 is an Akt-regulated myokine. FEBS Lett. 2008, 582, 3805-3810.
48. Tacer, K.F.; Bookout, A.L.; Ding, X.; Kurosu, H.; John, G.B.; Wang, L.; Goetz, R.; Mohammadi, M.; Kuro-o, M.; Mangelsdorf, D.J.; et al. Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol. Endocrinol. 2010, 24, 2050-2064.
49. Potthoff, M.J.; Kliewer, S.A.; Mangelsdorf, D.J. Endocrine fibroblast growth factors 15/19 and 21: From feast to famine. Genes Dev. 2012, 26, 312-324.
50. Woo, Y.C.; Xu, A.; Wang, Y.; Lam, K.S.L. Fibroblast Growth Factor 21 as an emerging metabolic regulator: Clinical perspectives. Clin. Endocrinol. 2013, 78, 489-496.
51. Badman, M.K.; Koester, A.; Flier, J.S.; Kharitonenkov, A.; Maratos-Flier, E. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 2009, 150, 4931-4940.
52. Badman, M.K.; Pissios, P.; Kennedy, A.R.; Koukos, G.; Flier, J.S.; Maratos-Flier, E. Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007, 5, 426-437.
53. Inagaki, T.; Dutchak, P.; Zhao, G.; Ding, X.; Gautron, L.; Parameswara, V.; Li, Y.; Goetz, R.; Mohammadi, M.; Esser, V.; et al. Endocrine Regulation of the Fasting Response by PPAR-α-Mediated Induction of Fibroblast Growth Factor 21. Cell Metab. 2007, 5, 415-425.
54. Dutchak, P.A.; Katafuchi, T.; Bookout, A.L.; Choi, J.H.; Yu, R.T.; Mangelsdorf, D.J.; Kliewer, S.A. Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. Cell 2012, 148, 556-567.
55. Xu, J.; Lloyd, D.J.; Hale, C.; Stanislaus, S.; Chen, M.; Sivits, G.; Vonderfecht, S.; Hecht, R.; Li, Y.-S.; Lindberg, R.A.; et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009, 58, 250-259.
56. Zhang, X.; Yeung, D.C.Y.; Karpisek, M.; Stejskal, D.; Zhou, Z.-G.; Liu, F.; Wong, R.L.C.; Chow, W.-S.; Tso, A.W.K.; Lam, K.S.L.; et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008, 57, 1246-1253.
57. Sjögren, K.; Liu, J.-L.; Blad, K.; Skrtic, S.; Vidal, O.; Wallenius, V.; Leroith, D.; Törnell, J.; Isaksson, O.G.P.; Jansson, J.-O.; et al. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc. Natl. Acad. Sci. USA 1999, 96, 7088-7092.
58. List, E.O.; Sackmann-Sala, L.; Berryman, D.E.; Funk, K.; Kelder, B.; Gosney, E.S.; Okada, S.; Ding, J.; Cruz-Topete, D.; Kopchick, J.J. Endocrine parameters and phenotypes of the growth hormone receptor gene disrupted (GHR-/-) mouse. Endocr. Rev. 2011, 32, 356-386.
59. Yakar, S.; Adamo, M.L. Insulin-like growth factor 1 physiology. Lessons from mouse models. Endocrinol. Metab. Clin. N. Am. 2012, 41, 231-247.
60. Inagaki, T.; Lin, V.Y.; Goetz, R.; Mohammadi, M.; Mangelsdorf, D.J.; Kliewer, S.A. Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab. 2008, 8, 77-83.
61. Fazeli, P.K.; Klibanski, A. Determinants of GH resistance in malnutrition. J. Endocrinol. 2014, 220, R57-R65.
62. Lam, C.K.L.; Chari, M.; Lam, T.K.T. CNS regulation of glucose homeostasis. Physiology 2009, 24, 159-170.
63. Thorens, B. Brain glucose sensing and neural regulation of insulin and glucagon secretion. Diabetes Obes. Metab. 2011, 13, 82-88.
64. Dunn-Meynell, A.A.; Sanders, N.M.; Compton, D.; Becker, T.C.; Eiki, J.I.; Zhang, B.B.; Levin, B.E. Relationship among brain and blood glucose levels and spontaneous and glucoprivic feeding. J. Neurosci. 2009, 29, 7015-7022.
65. Lam, T.K.T. Neuronal regulation of homeostasis by nutrient sensing. Nat. Med. 2010, 16, 392-395.
66. Burdakov, D.; Karnani, M.M.; Gonzalez, A. Lateral hypothalamus as a sensor-regulator in respiratory and metabolic control. Physiol. Behav. 2013, 121, 117-124.
67. Newman, J.C.; Verdin, E. Ketone bodies as signaling metabolites. Trends Endocrinol. Metab. 2014, 25, 42-52.
68. Paoli, A.; Rubini, A.; Volek, J.S.; Grimaldi, K.A. Beyond weight loss: A review of the therapeutic uses of very-low-carbohydrate (ketogenic) diets. Eur. J. Clin. Nutr. 2013, 67, 789-796.
69. Bestervelt, L.L.; Pitt, J.A.; Nolan, C.J.; Piper, W.N. TCDD alters pituitary-adrenal function II: Evidence for decreased bioactivity of ACTH. Neurotoxicol. Teratol. 1993, 15, 371-376.
70. Bestervelt, L.L.; Pitt, J.A.; Piper, W.N. Evidence for ah receptor mediation of increased ACTH concentrations in primary cultures of rat anterior pituitary cells exposed to TCDD. Toxicol. Sci. 1998, 46, 294-299.
71. Schuur, A.G.; Boekhorst, F.M.; Brouwer, A.; Visser, T.J. Extrathyroidal effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on thyroid hormone turnover in male Sprague-Dawley rats. Endocrinology 1997, 138, 3727-3734.
72. Pohjanvirta, R.; Laitinen, J.; Vakkuri, O.; Lindén, J.; Kokkola, T.; Unkila, M.; Tuomisto, J. Mechanism by which 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) reduces circulating melatonin levels in the rat. Toxicology 1996, 107, 85-97.
73. DiBartolemeis, M.J.; Moore, R.W.; Peterson, R.E.; Jefcoate, C.R. Hypercholesterolemia and the regulation of adrenal steroidogenesis in 2,3,7,8-tetrachlorodibenzo-p-dioxin-treated rats. Toxicol. Appl. Pharmacol. 1986, 85, 313-323.
74. Moore, R.W.; Jefcoate, C.R.; Peterson, R.E. 2,3,7,8-Tetrachlorodibenzo-p-dioxin inhibits steroidogenesis in the rat testis by inhibiting the mobilization of cholesterol to cytochrome P450scc. Toxicol. Appl. Pharmacol. 1991, 109, 85-97.
75. Brunnberg, S.; Svendebrog, E.; Gustafsson, J. Å. Functional interactions of AHR with other receptors. In The AH Receptor in Biology and Toxicology; Pohjanvirta, R., Ed.; John Wiley & Sons: Hoboken, NJ, USA, 2011.
76. Gorski, J.R.; Muzi, G.; Weber, L.W.; Pereira, D.W.; Arceo, R.J.; Iatropoulos, M.J.; Rozman, K. Some endocrine and morphological aspects of the acute toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Toxicol. Pathol. 1988, 16, 313-320.
77. Gorski, J.R.; Rozman, K. Dose-response and time course of hypothyroxinemia and hypoinsulinemia and characterization of insulin hypersensitivity in 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-treated rats. Toxicology 1987, 44, 297-307.
78. Novelli, M.; Piaggi, S.; de Tata, V. 2,3,7,8-Tetrachlorodibenzo-p-dioxin-induced impairment of glucose-stimulated insulin secretion in isolated rat pancreatic islets. Toxicol. Lett. 2005, 156, 307-314.
79. Tuomisto, J.T.; Laaksonen, M.; Viluksela, M.; Pohjanvirta, R.; Tuomisto, J. Minor changes in leptin levels after 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) exposure. Pharmacol. Toxicol. 1997, 80, 113-114.
80. Bertile, F.; Raclot, T. The melanocortin system during fasting. Peptides 2006, 27, 291-300.
81. Johansson, A.; Fredriksson, R.; Winnergren, S.; Hulting, A.-L.; Schiöth, H.B.; Lindblom, J. The relative impact of chronic food restriction and acute food deprivation on plasma hormone levels and hypothalamic neuropeptide expression. Peptides 2008, 29, 1588-1595.
82. Lensu, S.; Tiittanen, P.; Pohjanvirta, R. Circadian differences between two rat strains in their feeding and drinking micro-and macrostructures. Biol. Rhythm Res. 2011, 42, 385-405.
83. Cone, J.J.; McCutcheon, J.E.; Roitman, M.F. Ghrelin acts as an interface between physiological state and phasic dopamine signaling. J. Neurosci. 2014, 34, 4905-4913.
84. Lindén, J.; Korkalainen, M.; Lensu, S.; Tuomisto, J.; Pohjanvirta, R. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and leptin on hypothalamic mRNA expression of factors participating in food intake regulation in a TCDD-sensitive and a TCDD-resistant rat strain. J. Biochem. Mol. Toxicol. 2005, 19, 139-148.
85. Tuomisto, J.; Andrzejewski, W.; Unkila, M.; Pohjanvirta, R.; Lindén, J.; Vartiainen, T.; Tuomisto, L. Modulation of TCDD-induced wasting syndrome by portocaval anastomosis and vagotomy in Long-Evans and Han/Wistar rats. Eur. J. Pharmacol. 1995, 292, 277-285.
86. Moon, B.H.; Hong, C.G.; Kim, S.Y.; Kim, H.J.; Shin, S.K.; Kang, S.; Lee, K.J.; Kim, Y.K.; Lee, M.S.; Shin, K.H. A single administration of 2,3,7,8-tetrachlorodibenzo-p-dioxin that produces reduced food and water intake induces long-lasting expression of corticotropin-releasing factor, arginine vasopressin, and proopiomelanocortin in rat brain. Toxicol. Appl. Pharmacol. 2008, 233, 314-322.
87. Viluksela, M.; Unkila, M.; Pohjanvirta, R.; Tuomisto, J.T.; Stahl, B.U.; Rozman, K.K.; Tuomisto, J. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on liver phosphoenolpyruvate carboxykinase (PEPCK) activity, glucose homeostasis and plasma amino acid concentrations in the most TCDD-susceptible and the most TCDD-resistant rat strains. Arch. Toxicol. 1999, 73, 323-336.
88. Stahl, B.U.; Beer, D.G.; Weber, L.W.D.; Rozman, K. Reduction of hepatic phosphoenolpyruvate carboxykinase (PEPCK) activity by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is due to decreased mRNA levels. Toxicology 1993, 79, 81-95.
89. Oh, K.-J.; Han, H.-S.; Kim, M.-J.; Koo, S.-H. Transcriptional regulators of hepatic gluconeogenesis. Arch. Pharm. Res. 2013, 36, 189-200.
90. Pohjanvirta, R.; Tuomisto, J. Remarkable residual alterations in responses to feeding regulatory challenges in Han/Wistar rats after recovery from the acute toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Food Chem. Toxicol. 1990, 28, 677-686.
91. Pohjanvirta, R.; Unkila, M.; Tuomisto, J. The loss of glucoprivic feeding is an early-stage alteration in TCDD-treated Han/Wistar rats. Pharmacol. Toxicol. 1990, 67, 441-443.
92. Hectors, T.L.M.; Vanparys, C.; van Gaal, L.F.; Jorens, P.G.; Covaci, A.; Blust, R. Insulin resistance and environmental pollutants: Experimental evidence and future perspectives. Environ. Health Perspect. 2013, 121, 1273-1281.
93. Kern, P.A.; Said, S.; Jackson, W.G., Jr.; Michalek, J.E. Insulin sensitivity following Agent Orange exposure in Vietnam veterans with high blood levels of 2,3,7,8-tetrachlorodibenzo-p-dioxin. J. Clin. Endocrinol. Metab. 2004, 89, 4665-4672.
94. Berg, A.H.; Combs, T.P.; Du, X.; Brownlee, M.; Scherer, P.E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med. 2001, 7, 947-953.
95. Croutch, C.R.; Lebofsky, M.; Schramm, K.-W.; Terranova, P.F.; Rozman, K.K. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and 1,2,3,4,7,8-hexachlorodibenzo-p-dioxin (HxCDD) alter body weight by decreasing insulin-like growth factor I (IGF-I) signaling. Toxicol. Sci. 2005, 85, 560-571.
96. List, E.O.; Berryman, D.E.; Funk, K.; Jara, A.; Kelder, B.; Wang, F.; Stout, M.B.; Zhi, X.; Sun, L.; White, T.A.; et al. Liver-specific GH receptor gene disrupted (LiGHRKO) mice have decreased endocrine IGF-1, increased local IGF-1 as well as altered body size, body composition and adipokine profiles. Endocrinology 2014, 155, 1793-1805.
97. Moore, R.W.; Parsons, J.A.; Bookstaff, R.C.; Peterson, R.E. Plasma concentrations of pituitary hormones in 2,3,7,8-tetrachlorodibenzo-p-dioxin-treated male rats. J. Biochem. Toxicol. 1989, 4, 165-172.
98. Elango, A.; Shepherd, B.; Chen, T.T. Effects of endocrine disrupters on the expression of growth hormone and prolactin mRNA in the rainbow trout pituitary. Gen. Comp. Endocrinol. 2006, 145, 116-127.
99. Boutros, P.C.; Yao, C.Q.; Watson, J.D.; Wu, A.H.; Moffat, I.D.; Prokopec, S.D.; Smith, A.B.; Okey, A.B.; Pohjanvirta, R. Hepatic transcriptomic responses to TCDD in dioxin-sensitive and dioxin-resistant rats during the onset of toxicity. Toxicol. Appl. Pharmacol. 2011, 251, 119-129.
100. Clemmons, D.R.; Underwood, L.E. Nutritional regulation of IGF-I and IGF binding proteins. Annu. Rev. Nutr. 1991, 11, 393-412.
101. Sharma, N.; Castorena, C.M.; Cartee, G.D. Greater insulin sensitivity in calorie restricted rats occurs with unaltered circulating levels of several important myokines and cytokines. Nutr. Metab. 2012, 9, 90. doi:10.1186/1743-7075-9-90.
102. Lu, H.; Cui, W.; Klaassen, C.D. Nrf2 protects against 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-indsuced oxidative injury and steatohepatitis. Toxicol. Appl. Pharmacol. 2011, 256, 122-135.
103. Shaban, Z.; El-Shazly, S.; Abdelhady, S.; Fattouh, I.; Muzandu, K.; Ishizuka, M.; Kimura, K.; Kazusaka, A.; Fujita, S. Down regulation of hepatic PPARalpha function by AhR ligand. J. Vet. Med. Sci. 2004, 66, 1377-1386.
104. Berglund, E.D.; Kang, L.; Lee-Young, R.S.; Hasenour, C.M.; Lustig, D.G.; Lynes, S.E.; Donahue, E.P.; Swift, L.L.; Charron, M.J.; Wasserman, D.H. Glucagon and lipid interactions in the regulation of hepatic AMPK signaling and expression of PPARa and FGF21 transcripts in vivo. Am. J. Physiol.-Endocrinol. Metab. 2010, 299, E607-E614.
105. Arafat, A.M.; Kaczmarek, P.; Skrzypski, M.; Pruszynska-Oszmalek, E.; Kolodziejski, P.; Szczepankiewicz, D.; Sassek, M.; Wojciechowicz, T.; Wiedenmann, B.; Pfeiffer, A.F.H.; et al. Glucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: A novel mechanism of glucagon-stimulated lipolysis? Diabetologia 2013, 56, 588-597.
106. Lundåsen, T.; Hunt, M.C.; Nilsson, L.-M.; Sanyal, S.; Angelin, B.; Alexson, S.E.H.; Rudling, M. PPARa is a key regulator of hepatic FGF21. Biochem. Biophys. Res. Commun. 2007, 360, 437-440.
107. Pohjanvirta, R.; Sankari, S.; Kulju, T.; Naukkarinen, A.; Ylinen, M.; Tuomisto, J. Studies on the role of lipid peroxidation in the acute toxicity of TCDD in rats. Pharmacol. Toxicol. 1990, 66, 399-408.
108. Fletcher, N.; Wahlstrom, D.; Lundberg, R.; Nilsson, C.B.; Nilsson, K.C.; Stockling, K.; Hellmold, H.; Håkansson, H. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) alters the mRNA expression of critical genes associated with cholesterol metabolism, bile acid biosynthesis, and bile transport in rat liver: A microarray study. Toxicol. Appl. Pharmacol. 2005, 207, 1-24.
109. Christian, B.J.; Menahan, L.A.; Peterson, R.E. Intermediary metabolism of the mature rat following 2,3,7,8-tetrachlorodibenzo-p-dioxin treatment. Toxicol. Appl. Pharmacol. 1986, 83, 360-378.
110. Lakshman, M.R.; Ghosh, P.; Chirtel, S.J. Mechanism of action of 2,3,7,8-tetrachlorodibenzo-pdioxin on intermediary metabolism in the rat. J. Pharmacol. Exp. Ther. 1991, 258, 317-319.
111. Yao, C.Q.; Prokopec, S.D.; Watson, J.D.; Pang, R.; P'ng, C.; Chong, L.C.; Harding, N.J.; Pohjanvirta, R.; Okey, A.B.; Boutros, P.C. Inter-strain heterogeneity in rat hepatic transcriptomic responses to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Toxicol. Appl. Pharmacol. 2012, 260, 135-145.
112. Pohjanvirta, R.; Boutros, P.C.; Moffat, I.D.; Lindén, J.; Wendelin, D.; Okey, A.B. Genome-wide effects of acute progressive feed restriction in liver and white adipose tissue. Toxicol. Appl. Pharmacol. 2008, 230, 41-56.
113. Boone, L.; Meyer, D.; Cusick, P.; Ennulat, D.; Provencher Bolliger, A.; Everds, N.; Meador, V.; Elliott, G.; Honor, D.; Bounous, D.; et al. Selection and interpretation of clinical pathology indicators of hepatic injury in preclinical studies. Vet. Clin. Pathol. 2005, 34, 182-188.
114. Ennulat, D.; Magid-Slav, M.; Rehm, S.; Tatsuoka, K.S. Diagnostic performance of traditional hepatobiliary biomarkers of drug-induced liver injury in the rat. Toxicol. Sci. 2010, 116, 397-412.
115. Giannone, J.V.; Li, W.; Probst, M.; Okey, A.B. Prolonged depletion of AH receptor without alteration of receptor mRNA levels after treatment of cells in culture with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Biochem. Pharmacol. 1998, 55, 489-497.
116. Pollenz, R.S. The mechanism of AH receptor protein down-regulation (degradation) and its impact on AH receptor-mediated gene regulation. Chem. Biol. Interact. 2002, 141, 41
117. Franc, M.A.; Pohjanvirta, R.; Tuomisto, J.; Okey, A.B. In vivo up-regulation of aryl hydrocarbon receptor expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in a dioxin-resistant rat model. Biochem. Pharmacol. 2001, 62, 1565-1578.
118. MacPherson, L.; Ahmed, S.; Tamblyn, L.; Krutmann, J.; Förster, I.; Weighardt, H.; Matthews, J. Aryl hydrocarbon receptor repressor and TiPARP (ARTD14) use similar, but also distinct mechanisms to repress aryl hydrocarbon receptor signaling. Int. J. Mol. Sci. 2014, 15, 7939-7957.
119. Haarmann-Stemmann, T.; Abel, J. The arylhydrocarbon receptor repressor (AhRR): Structure, expression, and function. Biol. Chem. 2006, 387, 1195-1199.
120. Hahn, M.E.; Allan, L.L.; Sherr, D.H. Regulation of constitutive and inducible AHR signaling: Complex interactions involving the AHR repressor. Biochem. Pharmacol. 2009, 77, 485-497.
121. Dietrich, C. The AHR in the control of cell cycle and apoptosis. In The AH Receptor in Biology and Toxicology; Pohjanvirta, R., Ed.; John Wiley and Sons: Hoboken, NJ, USA, 2012; pp. 467-484.
122. Jackson, D.P.; Li, H.; Mitchell, K.A.; Joshi, A.D.; Elferink, C.J. Ah receptor-mediated suppression of liver regeneration through NC-XRE-driven p21Cip1 expression. Mol. Pharmacol. 2014, 85, 533-541.
123. Mitchell, K.A.; Lockhart, C.A.; Huang, G.; Elferink, C.J. Sustained aryl hydrocarbon receptor activity attenuates liver regeneration. Mol. Pharmacol. 2006, 70, 163-170.
124. Lee, J.S.; Cella, M.; McDonald, K.G.; Garlanda, C.; Kennedy, G.D.; Nukaya, M.; Mantovani, A.; Kopan, R.; Bradfield, C.A.; Newberry, R.D.; et al. AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of Notch. Nat. Immunol. 2011, 13, 144-151.
125. Lahvis, G.P.; Bradfield, C.A. Ahr null alleles: Distinctive or different? Biochem. Pharmacol. 1998, 56, 781-787.
126. Zhu, B.T.; Gallo, M.A.; Burger, C.W.; Meeker, R.J.; Cai, M.X.; Xu, S.; Conney, A.H. Effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin administration and high-fat diet on the body weight and hepatic estrogen metabolism in female C3H/HeN mice. Toxicol. Appl. Pharmacol. 2008, 226, 107-118.
127. Lindén, J.; Ranta, J.; Pohjanvirta, R. Bayesian modeling of reproducibility and robustness of RNA reverse transcription and quantitative real-time polymerase chain reaction. Anal. Biochem. 2012, 428, 81-91.
128. Bustin, S.A. Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): Trends and problems. J. Mol. Endocrinol. 2002, 29, 23-39.
129. Tichopad, A.; Kitchen, R.; Riedmaier, I.; Becker, C.; Ståhlberg, A.; Kubista, M. Design and optimization of reverse-transcription quantitative PCR experiments. Clin. Chem. 2009, 55, 1816-1823.